IBRX
ImmunityBio, Inc.
$7.10
-1.39%
$7.4B
No data for this timeframe.
Vol
Market Cap$7.4B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (90%)
Inst. Holders50 funds
Inst. Value$1.1B
Inst. Activity31 buys / 6 sells
Insider Activity0B / 4S
Insider Net $-$2.8M
Reddit Sentiment48° Neutral
SEC Reports4
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001326110·Prev Close $7.20
Recent Activity
Jun 9, 2026
Insider
Selecky Christobel was granted 65,600 shares
Director
Jun 9, 2026
Insider
Clark Wesley was granted 65,600 shares
Director
Jun 9, 2026
Insider
Cohen Cheryl was granted 65,600 shares
Director
May 29, 2026
short_volume
Short Volume: IBRX — 61.6% short (4.5M / 7.2M)
Short: 4,453,254 | Exempt: 30,836 | TRF Vol: 7,234,759 | Short Ratio: 61.6% | Off-exchange volume (d
May 18, 2026
SEC
ImmunityBio entered an exclusive U.S. development and supply agreement with Japan BCG Laboratory for the Tokyo-172 strai
8-K — Impact 5/10
Apr 9, 2026
SEC
ImmunityBio reported preliminary Q1 2026 net product revenue of $44.2 million, a 168% year-over-year increase, driven by
8-K — Impact 8/10
Apr 6, 2026
SEC
ImmunityBio submitted a comprehensive response to an FDA warning letter regarding promotional materials for its drug ANK
8-K — Impact 4/10
Inst.
VOLORIDGE INVESTMENT MANAGEMENT, LLC — NEW
2,927,552 shares ($22.5M)
Price Targets
$13.00
+83.1% upside
Strong Buy
Current $7.10
Low $12.00
Median $12.00
High $15.00
3 analysts
$12.00
$15.00
Analyst Ratings
4Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 2, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 21, 2026 | BTIG | REITERATE | Buy → Buy |
| May 20, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 5, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Apr 21, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.08 ▼ -26.3% | $-0.08 — $-0.08 | 20% YoY | 1 |
| Next Q | $-0.07 ▼ -16.7% | $-0.07 — $-0.07 | 0% YoY | 1 |
| Current FY | $-0.85 ▼ -220.8% | $-0.88 — $-0.81 | -124% YoY | 3 |
| Next FY | $0.06 ▲ +400.0% | $0.06 — $0.06 | 1 |
Latest Reports
BULLISH
8-K
5/10
ImmunityBio entered an exclusive U.S. development and supply agreement with Japan BCG Laboratory for the Tokyo-172 strai
May 18, 2026
BULLISH
8-K
8/10
ImmunityBio reported preliminary Q1 2026 net product revenue of $44.2 million, a 168% year-over-year increase, driven by
Apr 9, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $202.1M | ADD |
| STATE STREET CORP | $135.8M | ADD |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $125.2M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $116.0M | — |
| D. E. Shaw & | $96.4M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 9, 2026 | Selecky Christobel | A | $0.00 |
| Jun 9, 2026 | Clark Wesley | A | $0.00 |
| Jun 9, 2026 | Cohen Cheryl | A | $0.00 |
| Jun 9, 2026 | Wendel Bruce | A | $0.00 |
| Jun 9, 2026 | MAXWELL LINDA | A | $0.00 |
Reddit Sentiment
48°▼
Neutral
Bearish
Neutral
Bullish
50 institutional holders with $1.1B total value (145,774,336 shares) as of 2026-Q1. Top holders: BlackRock,, STATE, VANGUARD. Net buying activity: 31 institutions added/increased vs 6 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 26,346,443 | $202.1M | 18.1% | ADD +29.2% |
| 2 | STATE STREET CORP | 17,708,103 | $135.8M | 12.2% | ADD +45.4% |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 16,322,844 | $125.2M | 11.2% | — |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 15,127,714 | $116.0M | 10.4% | — |
| 5 | D. E. Shaw & Co., Inc. | 12,571,597 | $96.4M | 8.6% | — |
| 6 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 5,683,600 | $43.6M | 3.9% | — |
| 7 | TWO SIGMA INVESTMENTS, LP | 4,385,500 | $33.6M | 3.0% | ADD +80.9% |
| 8 | MORGAN STANLEY | 4,018,869 | $30.8M | 2.8% | ADD +51.4% |
| 9 | LMR Partners LLP | 3,824,900 | $29.3M | 2.6% | — |
| 10 | Woodline Partners LP | 3,447,346 | $26.4M | 2.4% | TRIM -34.9% |
| 11 | GOLDMAN SACHS GROUP INC | 3,237,078 | $24.8M | 2.2% | — |
| 12 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 2,927,552 | $22.5M | 2.0% | NEW |
| 13 | CITADEL ADVISORS LLC | 2,876,200 | $22.1M | 2.0% | — |
| 14 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2,477,941 | $19.0M | 1.7% | — |
| 15 | BANK OF AMERICA CORP /DE/ | 2,447,843 | $18.8M | 1.7% | ADD +44.0% |
| 16 | VANGUARD FIDUCIARY TRUST CO | 2,123,128 | $16.3M | 1.5% | — |
| 17 | CITADEL ADVISORS LLC | 1,954,100 | $15.0M | 1.3% | — |
| 18 | BARCLAYS PLC | 1,890,100 | $14.5M | 1.3% | — |
| 19 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1,833,400 | $14.1M | 1.3% | — |
| 20 | ROYAL BANK OF CANADA | 1,486,049 | $11.4M | 1.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | NEW | — | 2,927,552 | — | $22.5M | 2026-Q1 |
| FEDERATED HERMES, INC. | NEW | — | 1,386,591 | — | $10.6M | 2026-Q1 |
| Nuveen, LLC | ADD | 633,094 | 879,571 | +38.9% | $6.7M | 2026-Q1 |
| Pictet Asset Management Holding SA | DOUBLED | 33,667 | 830,137 | +2365.7% | $5.6M | 2026-Q1 |
| NATIONAL BANK OF CANADA /FI/ | DOUBLED | 84,700 | 608,774 | +618.7% | $4.7M | 2026-Q1 |
| FRANKLIN RESOURCES INC | DOUBLED | 87,073 | 491,093 | +464.0% | $3.8M | 2026-Q1 |
| DEUTSCHE BANK AG\ | ADD | 219,831 | 349,522 | +59.0% | $2.7M | 2026-Q1 |
| PRUDENTIAL FINANCIAL INC | DOUBLED | 16,140 | 268,370 | +1562.8% | $2.1M | 2026-Q1 |
| Invesco Ltd. | ADD | 182,836 | 267,490 | +46.3% | $2.1M | 2026-Q1 |
| STATE OF WISCONSIN INVESTMENT BOARD | DOUBLED | 83,538 | 252,348 | +202.1% | $1.9M | 2026-Q1 |
| Daiwa Securities Group Inc. | DOUBLED | 3,173 | 199,200 | +6178.0% | $1.5M | 2026-Q1 |
| VOYA INVESTMENT MANAGEMENT LLC | DOUBLED | 49,426 | 191,552 | +287.6% | $1.5M | 2026-Q1 |
| JANUS HENDERSON GROUP PLC | ADD | 118,739 | 157,439 | +32.6% | $1.2M | 2026-Q1 |
| COMMONWEALTH EQUITY SERVICES, LLC | ADD | 75,776 | 143,257 | +89.1% | $1.1M | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | DOUBLED | 24,704 | 110,009 | +345.3% | $843.8K | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | DOUBLED | 51,640 | 103,871 | +101.1% | $796.7K | 2026-Q1 |
| Russell Investments Group, Ltd. | DOUBLED | 21,958 | 92,548 | +321.5% | $709.8K | 2026-Q1 |
| CANADA PENSION PLAN INVESTMENT BOARD | TRIM | 172,800 | 84,500 | -51.1% | $648.1K | 2026-Q1 |
| ExodusPoint Capital Management, LP | NEAR_EXIT | 367,881 | 84,309 | -77.1% | $646.6K | 2026-Q1 |
| AMERIPRISE FINANCIAL INC | ADD | 37,792 | 64,523 | +70.7% | $494.9K | 2026-Q1 |
| HighTower Advisors, LLC | ADD | 33,512 | 55,880 | +66.7% | $428.6K | 2026-Q1 |
| CWM, LLC | ADD | 37,311 | 47,081 | +26.2% | $361.1K | 2026-Q1 |
| Mariner, LLC | DOUBLED | 17,814 | 43,374 | +143.5% | $332.7K | 2026-Q1 |
| Beacon Pointe Advisors, LLC | ADD | 32,046 | 40,227 | +25.5% | $308.5K | 2026-Q1 |
| SEI INVESTMENTS CO | TRIM | 78,035 | 39,330 | -49.6% | $301.7K | 2026-Q1 |
11 unique insiders with 26 transactions. Net insider value: -$2.8M ($0.00 bought, $2.8M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 9, 2026 | Selecky Christobel | Director | AWARD | 65,600 | — | — |
| Jun 9, 2026 | Clark Wesley | Director | AWARD | 65,600 | — | — |
| Jun 9, 2026 | Cohen Cheryl | Director | AWARD | 65,600 | — | — |
| Jun 9, 2026 | Wendel Bruce | Director | AWARD | 65,600 | — | — |
| Jun 9, 2026 | MAXWELL LINDA | Director | AWARD | 65,600 | — | — |
| Jun 9, 2026 | BLASZYK MICHAEL D | Director | AWARD | 65,600 | — | — |
| Jun 4, 2026 | Simon Barry J. | Director | SELL | 23,033 | $7.18 | $165.3K |
| Mar 31, 2026 | SOON-SHIONG PATRICK | See remarks | CONVERT | 4,606,596 | $5.43 | $25.0M |
| Mar 31, 2026 | SOON-SHIONG PATRICK | See remarks | CONVERT | 25,000,000 | — | — |
| Feb 24, 2026 | Simon Barry J. | Director | SELL | 75,000 | $12.01 | $900.8K |
| Feb 23, 2026 | Simon Barry J. | Director | SELL | 165,000 | $10.25 | $1.7M |
| Feb 23, 2026 | Selecky Christobel | Director | EXERCISE | 25,000 | $2.98 | $74.5K |
| Feb 22, 2026 | Simon Barry J. | Director | EXERCISE | 15,243 | — | — |
| Feb 22, 2026 | Adcock Richard | CEO & President | EXERCISE | 152,439 | — | — |
| Feb 22, 2026 | SOON-SHIONG PATRICK | See remarks | EXERCISE | 114,329 | — | — |
| Feb 22, 2026 | LAUER REGAN J | Chief Accounting Officer | EXERCISE | 4,065 | — | — |
| Feb 22, 2026 | Sachs David C. | Chief Financial Officer | EXERCISE | 40,650 | — | — |
| Feb 20, 2026 | Simon Barry J. | Director | SELL | 10,000 | $9.25 | $92.5K |
| Feb 10, 2026 | SOON-SHIONG PATRICK | See remarks | EXERCISE | 274,122 | — | — |
| Feb 10, 2026 | SOON-SHIONG PATRICK | See remarks | TAX W/H | 118,560 | $6.93 | $821.6K |
| Feb 10, 2026 | Sachs David C. | Chief Financial Officer | EXERCISE | 82,236 | — | — |
| Feb 10, 2026 | Sachs David C. | Chief Financial Officer | TAX W/H | 42,643 | $6.93 | $295.5K |
| Feb 10, 2026 | LAUER REGAN J | Chief Accounting Officer | EXERCISE | 5,482 | — | — |
| Feb 10, 2026 | LAUER REGAN J | Chief Accounting Officer | TAX W/H | 2,257 | $6.93 | $15.6K |
| Feb 10, 2026 | Adcock Richard | CEO & President | EXERCISE | 274,122 | — | — |
| Feb 10, 2026 | Adcock Richard | CEO & President | TAX W/H | 140,048 | $6.93 | $970.5K |
4 SEC filing reports analyzed. Sentiment: 3 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 5.8/10.
BULLISH
8-K
5/10
ImmunityBio entered an exclusive U.S. development and supply agreement with Japan BCG Laboratory for
May 18, 2026
BULLISH
8-K
8/10
ImmunityBio reported preliminary Q1 2026 net product revenue of $44.2 million, a 168% year-over-year
Apr 9, 2026
NEUTRAL
8-K
4/10
ImmunityBio submitted a comprehensive response to an FDA warning letter regarding promotional materi
Apr 6, 2026
BULLISH
INST-CLUSTER
6/10
Three major passive institutional investors — Morgan Stanley, Wells Fargo, and UBS — increased their
Feb 28, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (90% buy). Based on 10 analysts: 4 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$13.00 mean target
+83.1% upside
Strong Buy (1.33)
$12.00 Low
$15.00 High
| Metric | Value |
|---|---|
| Current Price | $7.10 |
| Target Low | $12.00 |
| Target Mean | $13.00 |
| Target Median | $12.00 |
| Target High | $15.00 |
| # Analysts | 3 |
| Recommendation | Strong Buy (1.33) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.08 | $-0.08 | $-0.08 | 20.0% | -26.3% | 1↑ 1↓ | $0.0B | 86.2% | 1 |
| Next Q 2026-09-30 |
$-0.07 | $-0.07 | $-0.07 | 0.0% | -16.7% | 1↑ 1↓ | $0.1B | 79.8% | 1 |
| Current FY 2026-12-31 |
$-0.85 | $-0.88 | $-0.81 | -123.7% | -220.8% | 0↑ 1↓ | $0.2B | 96.3% | 3 |
| Next FY 2027-12-31 |
$0.06 | $0.06 | $0.06 | — | +400.0% | 0↑ 1↓ | $0.5B | 103.3% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.080 | |
| 7d ago | $-0.070 | -0.010 |
| 30d ago | $-0.063 | -0.017 |
| 60d ago | $-0.063 | -0.017 |
| 90d ago | $-0.070 | -0.010 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 2, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 21, 2026 | BTIG | REITERATE | Buy | Buy |
| May 20, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 5, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Apr 21, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Apr 8, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 26, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 23, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 17, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 9, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 4, 2026 | Piper Sandler | REITERATE | Overweight | Overweight |
| Feb 23, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Feb 23, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 19, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Feb 17, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 26, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 23, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 23, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Jan 20, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Jan 20, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 16, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 13, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 5 | 1 | 0 | 0 | 90% | |
| May 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| Apr 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| Mar 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| Feb 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| Jan 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
48°
Neutral
Bearish
Neutral
Bullish
23 mentions
5 bullish
6 bearish
20 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 22, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 21, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 21, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 21, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 21, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 11, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 11, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 27, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Apr 27, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Apr 17, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Apr 17, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Mar 18, 2026 | 3 | 57° Neutral | 1 | 0 | 3 |
| Mar 18, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 12, 2026 | 2 | 50° Neutral | 0 | 0 | 2 |
| Feb 28, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Feb 25, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Feb 24, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Feb 19, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 9, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Feb 5, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
Does anyone know anything about IBRX
▲ 1
💬 1
⚡ 0.5
The r/pennystocks lounge is DYING - we need to SAVE IT
▲ 1
💬 0
⚡ 0.5
How do you feel about SLS and IBRX?
▲ 1
💬 1
⚡ 0.5
IBRX VS PLTR
▲ 1
💬 0
⚡ 0.5
25 MATCH 2026 , BIGGEST LOSERS IN THE PRE- MARKET
▲ 1
💬 1
⚡ 0.5
#IBRX Thoughts ?
▲ 1
💬 0
⚡ 0.5
#IBRX thoughts 🤔
▲ 1
💬 0
⚡ 0.5
#IBRX 💯🚀💎💎
▲ 1
💬 1
⚡ 0.5
IBRX is now in play
▲ 1
💬 0
⚡ 0.5
Running IBRX
▲ 1
💬 0
⚡ 0.5
Best performing stocks year-to-date by market cap
▲ 1
💬 0
⚡ 0.5
On February 24, 2026, several Russell 2000 healthcare and biotech stocks reached new 52-week highs
▲ 0
💬 0
An interesting possible entry ($IBRX)
▲ 1
💬 0
⚡ 0.0
Uncapping a 5/10 call spread — would you here?
▲ 7
💬 5
⚡ 0.1
IBRX shorts are fucked!
▲ 2
💬 4
⚡ 0.0
May 29, 2026
short_volume
Short Volume: IBRX — 61.6% short (4.5M / 7.2M)
Short: 4,453,254 | Exempt: 30,836 | TRF Vol: 7,234,759 | Short Ratio: 61.6% | Off-exchange volume (dark pool + OTC)
May 28, 2026
short_volume
Short Volume: IBRX — 60.5% short (3.5M / 5.8M)
Short: 3,521,893 | Exempt: 13,606 | TRF Vol: 5,820,520 | Short Ratio: 60.5% | Off-exchange volume (dark pool + OTC)
May 26, 2026
Clinical Trial
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
Phase Phase 3 — TERMINATED
May 22, 2026
short_volume
Short Volume: IBRX — 66.7% short (6.8M / 10.1M)
Short: 6,751,868 | Exempt: 36,105 | TRF Vol: 10,117,707 | Short Ratio: 66.7% | Off-exchange volume (dark pool + OTC)
May 21, 2026
short_volume
Short Volume: IBRX — 69.0% short (8.2M / 11.8M)
Short: 8,162,930 | Exempt: 15,272 | TRF Vol: 11,829,223 | Short Ratio: 69.0% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: IBRX — 67.1% short (5.9M / 8.7M)
Short: 5,869,196 | Exempt: 47,895 | TRF Vol: 8,747,588 | Short Ratio: 67.1% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: IBRX — 68.8% short (4.2M / 6.1M)
Short: 4,173,759 | Exempt: 15,737 | TRF Vol: 6,065,114 | Short Ratio: 68.8% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: IBRX — 61.7% short (3.2M / 5.2M)
Short: 3,199,881 | Exempt: 19,587 | TRF Vol: 5,185,412 | Short Ratio: 61.7% | Off-exchange volume (dark pool + OTC)
May 8, 2026
short_interest
FTD: IBRX — 87,758 shares ($0.7M) failed to deliver
Settlement: 20260508, Price: $7.76, FTD Value: $681,002.08, IMMUNITYBIO INC COM (DE)
May 7, 2026
earnings_calendar
IBRX Q1 2026 Earnings Scheduled — 2026-05-07
May 7, 2026
short_interest
FTD: IBRX — 84,258 shares ($0.7M) failed to deliver
Settlement: 20260507, Price: $8.38, FTD Value: $706,082.04, IMMUNITYBIO INC COM (DE)
May 6, 2026
short_interest
FTD: IBRX — 175,248 shares ($1.3M) failed to deliver
Settlement: 20260506, Price: $7.58, FTD Value: $1,328,379.84, IMMUNITYBIO INC COM (DE)
May 5, 2026
short_volume
Short Volume: IBRX — 59.2% short (3.1M / 5.3M)
Short: 3,131,662 | Exempt: 27,162 | TRF Vol: 5,286,563 | Short Ratio: 59.2% | Off-exchange volume (dark pool + OTC)
May 4, 2026
short_interest
FTD: IBRX — 186,036 shares ($1.3M) failed to deliver
Settlement: 20260504, Price: $7.11, FTD Value: $1,322,715.96, IMMUNITYBIO INC COM (DE)
May 1, 2026
short_interest
FTD: IBRX — 81,295 shares ($0.6M) failed to deliver
Settlement: 20260501, Price: $7.10, FTD Value: $577,194.5, IMMUNITYBIO INC COM (DE)
May 1, 2026
short_volume
Short Volume: IBRX — 64.4% short (2.9M / 4.5M)
Short: 2,886,557 | Exempt: 36,477 | TRF Vol: 4,485,317 | Short Ratio: 64.4% | Off-exchange volume (dark pool + OTC)
Apr 15, 2026
Clinical Trial
HCW9218 for Advanced Pancreatic Cancer
Phase Phase 2 — COMPLETED